RSV
120 likes | 325 Vues
Learn about RSV, a common virus that manifests as bronchiolitis or viral pneumonia, affecting mainly infants due to smaller airways and reduced immune systems. Discover the risk factors, diagnosis, symptoms, management, and prevention strategies.
RSV
E N D
Presentation Transcript
RSV RT 265
Respiratory Syncytial Virus Manifests primarily as: • Bronchiolitis • Viral pneumonia Leading cause of lower respiratory tract infection in infants
Syncytium: Multinucleate mass of protoplasm produced by the merging of neighboring cells
Incidence • Peak ages 2-8months • Usually >4years old • Mid-winter and spring months • Virtually all children have been exposed by 3rd birthday • Disease is mild in older children and adults (upper respiratory tract) • WHY THE LITTLE ONES? • Smaller airways • Reduced immune system • High-risk groups for severe RSV infection include the following: • premature infants in their first year of life (the younger the child is [gestational and chronological age] at the start of RSV season, the greater the risk) • Infants with chronic lung disease (eg, bronchopulmonary dysplasia,cystic fibrosis) during their first 2 years of life • Children with hemodynamically significant congenital heart disease, especially with increased pulmonary blood flow • Immunodeficient states • Children with metabolic and neuromuscular disorders • Children of multiple births (triplets or greater)
Diagnosis • Correlate symptoms with the time of year, presence of a regional outbreak, patient age, and history of the illness • Specific diagnostics testing: • Nasal swabs • Nasal lavage • Nasopharyngeal aspiration • CXR hyperinflation diffuse increase in interstitial markings
Presentation • Fever • Cough • Tachypnea • Retractions • Wheezing • Crackles • Sepsis like symptoms • Apneic episodes in the very young • Diffuse small airway disease
Management Supportive care Can be managed at home unless requiring: • Supplemental oxygen • Fluid replacement – normal feeding or IV if unable • Bronchial hygiene - suctioning • Bronchodilators? (alpha and beta agonists) • Ribavirin (Virazole) • Mechanical ventilation/CPAP Prevention • WASH YOUR HANDS • Avoid mucus membrane exposure • Palivizumab (Synagis) antiviral immunoglobulins /motavizumab (investigational – not FDA approved)
The “best” part: No lifelong immunity develops! Reinfection is common